# A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

> **NCT05213624** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 67 (actual)

## Conditions studied

- Kidney Disease, Chronic

## Interventions

- **DRUG:** BI 764198
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05213624
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-01-03
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213624, "A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05213624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*